SINOMED(688108) 搜狐财经·2025-04-04 02:46Core Viewpoint - Sino Medical (688108) has received regulatory approval for its SC HONKYTONKTM coronary balloon dilation catheter in Malaysia, which is expected to enhance its overseas sales potential [1] Company Performance - As of March 28, 2025, Sino Medical's stock closed at 10.88 yuan, a decrease of 0.09% from the previous week [1] - The stock reached a weekly high of 11.08 yuan and a low of 10.35 yuan on March 24, 2025 [1] - The company's current total market capitalization is 4.461 billion yuan, ranking 69th out of 124 in the medical device sector and 3125th out of 5140 in the A-share market [1] Product Development - The SC HONKYTONKTM catheter is designed for the dilation of narrowed segments in coronary arteries, featuring a small delivery diameter, good compliance, and re-crossability [1] - The product has already received medical device registration from the National Medical Products Administration of China in December 2022 and is expected to obtain FDA certification in the U.S. and registrations in several other countries between 2023 and 2025 [1] - The recent approval in Malaysia is anticipated to boost the company's international sales, although potential impacts from various factors remain uncertain [1]